Triphasic oral contraceptives: Review and comparison of various regimens

Fertility and Sterility

Volumn 77, Issue 1, 2002, Pages 1-14

  Cedars, Marcelle I ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

3rd generation contraceptives; Birth control pills; Oral contraceptives; Triphasic contraceptives

Indexed keywords

CYCLESSA; DESOGESTREL; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NORETHISTERONE; ETHINYLESTRADIOL PLUS NORGESTIMATE; GESTAGEN; GESTODENE; LEVONORGESTREL; MESTRANOL PLUS NORETHISTERONE; NORETHISTERONE; NORGESTIMATE; TRIPHASIC CONTRACEPTIVE AGENT; TRIVORA;

BREAST DISEASE; CARBOHYDRATE METABOLISM; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; ECTOPIC PREGNANCY; ENDOMETRIUM CANCER; HEALTH; HEMOSTASIS; HUMAN; IRON DEFICIENCY ANEMIA; ISCHEMIC HEART DISEASE; LIPID METABOLISM; LITERATURE; MENORRHAGIA; MENSTRUAL CYCLE; MENSTRUAL IRREGULARITY; MENSTRUATION; ORAL CONTRACEPTION; OUTCOMES RESEARCH; OVARY CANCER; OVARY CYST; PELVIC INFLAMMATORY DISEASE; PREGNANCY; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS;

EID: 0036146473     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0015-0282(01)02927-2     Document Type: Review

References (73)

1. OC practice guidelines: Minimizing side effects
2. New progestogens in oral contraception
3. Review: The new low dose oral contraceptives
4. Efficacy, cycle control and safety of a triphasic desogestrel/ethinyl estradiol and Ortho-Novum™ 7/7/7 (triphasic norethindrone/ethinyl estradiol): A randomized clinical trial
5. Desogestrel, norgestimate, and gestodene: The newer progestins
6. Evaluation of the clinical performance of three triphasic oral contraceptives: A multicenter, randomized comparative trial
7. Rationale for a new triphasic oral contraceptive
8. Phasic approach to oral contraceptives
9. The triphasics: Insights for effective clinical use
10. Triphasic combination of ethinyl estradiol and gestodene. Long-term clinical trial
11. Estrogens and progestins
12. Efficacy, cycle control, and side effects of low- and lower-dose oral contraceptives: A randomized trial of 20 μg and 35 μg estrogen preparations
13. Selectivity in progesterone and androgen receptor binding of progestagens used in oral contraceptives
14. A low-dose triphasic oral contraceptive
15. Comparative contraceptive efficacy and mechanism of action of the norgestimate-containing triphasic oral contraceptive
16. Multicenter randomized comparative trial of two low-dose triphasic combined oral contraceptives containing desogestrel or norethindrone
17. Safety and efficacy of a triphasic oral contraceptive containing desogestrel: Results of three multicenter trials
18. Clinical evaluation of a new triphasic oral contraceptive: Norgestimate and ethinyl estradiol
19. A clinical overview of a new triphasic contraceptive containing gestodene
20. Triphasic randomized clinical trial: Comparative frequency of intermenstrual bleeding
21. Evaluation and therapy of breakthrough bleeding in women using a triphasic oral contraceptive
22. Reference period analysis of vaginal bleeding with triphasic oral contraceptive agents containing norethindrone or levonorgestrel: A comparison study
23. Cycle control with triphasic norgestimate and ethinyl estradiol, a new oral contraceptive agent
24. Results of a clinical study with low-dose oral contraceptives
25. A comparative analysis of three different dose combinations of oral contraceptives
26. Oral contraceptives and cycle control: A critical review of the literature
27. The androgenicity of progestins
28. Androgenic effects of oral contraceptives: Implications for patient compliance
29. Changes in androgens during treatment with four low-dose contraceptives
30. Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: A randomized, placebo-controlled trial
31. Clinical and hormonal effects of ethinyestradiol combined with gestodene and desogestrel in young women with acne vulgaris
32. Multicenter trial of two monophasic oral contraceptives containing 30 mcg ethinylestradiol and either desogestrel or gestodene in Thai women
33. Effects of a low-dose desogestrel-ethinylestradiol combination on hirsutism, androgens and sex hormone binding globulin in women with a polycystic ovary syndrome
34. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism
35. The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use
36. Lipid, carbohydrate, and androgen metabolism in women using a triphasic oral contraceptive containing norethindrone for one year
37. Comparative metabolic effects of three types of combined oral contraceptive pills in Chinese women
38. Effect of long-term triphasic oral contraceptive use on glucose tolerance and insulin secretion
39. Triphasic randomized clinical trial: Comparison of effects on carbohydrate metabolism
40. Metabolic effects of two low-dose triphasic oral contraceptives containing ethinyl estradiol and levonorgestrel or gestodene
41. Lipid and carbohydrate effects of a new triphasic oral contraceptive containing norgestimate
42. Carbohydrate metabolic studies in women using levonorgestrel/ethinyl estradiol containing triphasic oral contraceptive for eighteen months
43. Plasma glucose and insulin levels in women using a levonorgestrel-containing triphasic oral contraceptive for three months
44. The clinical aspects of estrogen and the cardiovascular system
45. Effects of three combined oral contraceptive preparations containing desogestrel plus ethinyl estradiol on lipid metabolism in comparison with two levonorgestrel preparations
46. Comparison of the lipoprotein and hemostatic changes after a triphasic and a monophasic low dose oral contraceptive in premenopausal middle-aged women
47. Metabolic effects and efficacy of a triphasic oral contraceptive (norgestimate/ethinyl estradiol)
48. Influence of a triphasic oral contraceptive preparation on plasma lipids and lipoproteins
49. A comparison study of lipid and androgen metabolism with triphasic oral contraceptive formulations containing norgestimate or levonorgestrel
50. Effects of three low-dose oral contraceptive formulations on lipid metabolism
51. The effect of triphasic oral contraceptives on plasma lipids and lipoproteins
52. A comparative study of the effects of a monophasic and a triphasic oral contraceptive containing ethinyl estradiol and levonorgestrel on lipid and lipoprotein metabolism
53. The effect of triphasic and biphasic oral contraceptive preparations on HDL-cholesterol and LDL-cholesterol in young women
54. Lipoprotein alterations from a triphasic oral contraceptive containing ethinyl estradiol and gestodene. A 12-month trial
55. Clinical and metabolic effects of a triphasic pill containing gestodene
56. Oral contraceptives and venous thromboembolism
57. The increased risk of venous thromboembolism and the use of third generation progestagens: Role of bias in observational research
58. The estrogen component of OCs: Cardiovascular benefits and risks
59. Population-based study of risk of venous thromboembolism associated with various oral contraceptives
60. Influence of triphasic oral contraceptives on blood rheology and hemostatic and metabolic patterns in young women. Results of a three-year study
61. Effects of two triphasic oral contraceptives containing ethinylestradiol plus levonorgestrel or gestodene on blood coagulation and fibrinolysis
62. Changes in coagulation and anticoagulation in women taking low-dose triphasic oral contraceptives: A controlled comparative 12-month clinical trial
63. Correcting misconceptions about oral contraceptives
64. The evolution of oral contraceptives: Maximizing efficacy, minimizing risks
65. Developments in contraception: A comprehensive review of Desogen (desogestrel and ethinyl estradiol)
66. Benefits and risks of oral contraceptives
67. Oral contraceptives and cancer. A review of the evidence